GLP-1 series
Module 7 · The exit plan
Weight Regain After GLP-1 Discontinuation
Stopping therapy tends to reverse the gains. The regain trajectory, who is at highest risk, and how to plan the off-ramp before it happens.
10 slides · 10 minutes
Video coming soon
10-minute recorded module
What this module covers
- 01What happens after the last dose
- 02The regain trajectory, illustrated
- 03Cardiometabolic markers that drift back
- 04Coverage interruptions as a clinical event
- 05Maintenance dosing and structured tapering
- 06Building the off-ramp into the initial plan
Key takeaways
Discontinuation is a predictable clinical event, not a failure.
Coverage loss and clinical stopping need different plans.
Maintenance strategy belongs in the first conversation.
Continue the series
Module 1
GLP-1–Based Therapies in Cardio-Oncology
Module 2
GLP-1 Receptor Agonist Therapy: The Complete Briefing
Module 3
Obesity, Cardiometabolic Health & GLP-1 Therapies
Educational information only. It does not replace advice from your oncology or primary care team, and no treatment decision should be made from this module alone.